Contract facts
FederalOCQC INCIDENT MANAGEMENT SUPPORT FOR COMPOUND DRUG OVERSIGHT is a federal award for Fda Office Of Acq Grant Svcs held by Kaiva Strategies, LLC. Estimated value $1.4M ($467K obligated). Current period of performance ends Aug 30, 2027 (potential Aug 30, 2029). Place of performance: IVINS UT.
OCQC INCIDENT MANAGEMENT SUPPORT FOR COMPOUND DRUG OVERSIGHT
Recompete timing
PublicCurrent PoP ends Aug 30, 2027 (374 days remaining). Agencies typically plan 12–18 months ahead — position before the PoP clock runs out.
Incumbent footprint
Public recordKaiva Strategies, LLC — $90.5M obligated across 68 awards (firm-wide, all agencies).
Related awards
Same parent · incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 75F40126F19035?
75F40126F19035 (OCQC incident management support) is a Fda Office Of Acq Grant Svcs award with a potential value of $1.4M, currently held by Kaiva Strategies, LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded 75F40126F19035?
Fda Office Of Acq Grant Svcs awarded 75F40126F19035 to Kaiva Strategies, LLC (potential $1.4M).
Who is the incumbent on 75F40126F19035?
Kaiva Strategies, LLC is the incumbent with $90.5M across 68 related awards in SCOUT’s public footprint. The current period of performance ends Aug 30, 2027.
When does Kaiva Strategies, LLC’s 75F40126F19035 come up for recompete?
SCOUT tracks a period-of-performance end of Aug 30, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.